The first drug evaluated through the EBP was trastuzumab in combination with chemotherapy for the adjuvant treatment of small, early HER2-positive breast cancer, which allowed clinicians and patients access to this treatment while Cancer Care Ontario collected additional data. Here, ERBB2 is linked to cancer.